Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued access and safety study of AZD1775 in advanced solid tumors
NL-OMON47273Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of adavosertib in Nonhematologic neoplasms, sponsored by AstraZeneca. Primary endpoints: Safety of AZD1775 monotherapy and Safety and tolerability following oral dosing. Started Oct 2017; status: active, not recruiting.
02
Drugs
adavosertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON47273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47273.